This architectural surprise matters because it solves one of the most stubborn problems in drug delivery: the sustained release of hydrophilic, or water-loving, drugs. Molecules that dissolve readily in water tend to leak out of conventional liposomes rapidly, producing a burst release that drains most of the payload within hours or days. For applications that demand drug levels to be maintained over weeks—long-acting analgesia, psychiatric medications, or depot formulations for chronic disease—that burst behavior has been a fundamental obstacle. The new multicompartment liposomes suppress burst release almost entirely and enable what the authors describe as ultra-slow release kinetics.

The practical payoff was demonstrated in a rat model of regional anesthesia. When the multilamellar–multivesicular liposomes were loaded with tetrodotoxin, a potent hydrophilic sodium-channel blocker, they produced a sciatic nerve block lasting several weeks. Nerve blocks with conventional formulations of local anesthetics typically last hours to at most a day or two. A weeks-long block from a single injection, if it can be translated safely to patients, could transform postoperative pain management, reducing or eliminating the need for opioid analgesics after major surgery.

To understand why the finding is unexpected, it helps to consider lipid phase behavior. Saturated phospholipids, with straight hydrocarbon tails, pack tightly into ordered gel-phase membranes and are the traditional building blocks of multilamellar vesicles used for slow release. Unsaturated phospholipids, by contrast, carry kinks in their tails where double bonds interrupt the chain. Those kinks frustrate tight packing, keeping membranes fluid and permeable—which is precisely why unsaturated lipids dominate the composition of many clinically approved liposomal drugs designed for efficient release and circulation. The intuition, therefore, has been that unsaturated lipids are poorly suited to retention-based, slow-release formulations.

Wang and colleagues found the opposite. When formulated under their conditions, unsaturated phospholipids self-organized into complex, hierarchical vesicles in which multiple bilayers are wrapped around, or packed alongside, multiple aqueous compartments. A hydrophilic drug loaded into these internal aqueous spaces must diffuse across several lipid barriers and traverse tortuous pathways between compartments before it can reach the surrounding tissue. Each bilayer acts as a diffusion barrier, and the compartmentalized geometry multiplies the effective path length. The result is a release profile that unfolds over days and weeks rather than minutes and hours, without the initial burst that plagues single-compartment vesicles.

Efficient encapsulation is the other half of the achievement. Hydrophilic drugs partition into the aqueous volume of liposomes, but in unilamellar vesicles that volume is limited and the enclosing membrane is thin, so leakage is rapid. In the multivesicular architecture, the internal aqueous volume is substantially larger and subdivided into many isolated reservoirs. Even if some compartments rupture or empty early, others remain sealed, smoothing the release curve. The study reports that these structures encapsulate hydrophilic drugs efficiently and retain them until the lipid matrix itself degrades or remodels slowly in tissue.

The broader context is a field increasingly focused on long-acting formulations. Reviews by Li and colleagues in Nature Reviews Materials and by Gao, Karp, Langer and Joshi in Chemistry of Materials have argued that extending the duration of action of drugs is one of the central challenges of pharmaceutical science, particularly for molecules that the body clears quickly. Injectable depots, implants and in situ gels all attempt to hold a drug near its target and meter it out slowly, but each carries trade-offs in invasiveness, reproducibility and manufacturability. Liposomes have long been attractive because they are biocompatible, biodegradable and produced at scale—yet their classic limitation with hydrophilic payloads has kept them out of most long-acting applications.

Previous efforts to slow liposomal release have included manipulating membrane cholesterol content, crosslinking bilayers, polymer-coating vesicles, and, most recently, engineering the lipid chemistry itself. A 2023 study in Nature Communications by Li and colleagues reported aromatized liposomes in which modified phospholipids increased drug loading, slowed release and improved in vivo efficacy, illustrating the strategy of tailoring lipid structure to retention goals. The new work is notable because it achieves the same ends not by designing exotic molecules but by exploiting an unexpected self-assembly behavior of ordinary unsaturated phospholipids—the workhorses already used across the liposome industry. If a standard, clinically familiar lipid class can be coaxed into a depot architecture through formulation rather than synthesis, the path to translation could be considerably shorter.

Caution is warranted, as with any preclinical result. The weeks-long nerve block was demonstrated in rats, and the dose, tolerability, reversibility and tissue response of a multiweek anesthetic block in humans remain open questions. A block that lasts weeks is only desirable if it can be timed and, when necessary, reversed; prolonged numbness or weakness could itself cause harm. The authors’ tetrodotoxin payload is a neurotoxin whose safety margin in clinical use would demand exceptionally precise control of release rates—precisely the control the multivesicular architecture appears to provide, but at a stringency that regulatory science has rarely been asked to certify. Questions about batch-to-batch consistency of such hierarchical structures, and about how they behave in tissues other than peripheral nerve, will shape the next stages of development.

Even so, the conceptual contribution is likely to endure. The study reframes a class of lipids long considered unsuitable for depot formation into a platform for ultra-slow release, and it suggests that the phase behavior of unsaturated membranes is richer than the field assumed. Multilamellar–multivesicular liposomes add a distinct mechanism to the slow-release toolbox described in recent reviews: retention by nested, compartmentalized barriers rather than by membrane rigidity or polymer matrices. For the growing list of hydrophilic drugs— biologics, neurotransmitter modulators, ion-channel blockers—that would benefit from weeks of controlled exposure, the finding opens a formulation route built from molecules the pharmaceutical industry already knows how to make, purify and approve. The distance between a rat’s sciatic nerve and a patient’s postoperative recovery remains considerable, but the first demonstration that a simple lipid recipe can hold water-soluble medicine for weeks is the kind of result from which translational stories often begin.

Subject of Research: Multilamellar–multivesicular liposomes formed by unsaturated phospholipids for ultra-slow release of hydrophilic drugs

Article Title: Unsaturated phospholipids form multicompartment liposomes that extend release of hydrophilic drugs

Article References: Unsaturated phospholipids form multicompartment liposomes that extend release of hydrophilic drugs. (2026). Nature Biomedical Engineering. https://doi.org/10.1038/s41551-026-01791-8

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01791-8

Keywords: liposomes, drug delivery, phospholipids, hydrophilic drugs, sustained release, multilamellar vesicles, tetrodotoxin, nerve block, long-acting formulations, biomedical engineering, self-assembly, anesthesia